Catálogo de publicaciones - revistas

<jats:title>Physical traits of cancer</jats:title> <jats:p> The biological and physical properties of tumors contribute to their growth and to treatment outcome. Although intense research efforts have helped to delineate cancer biology, the physics of cancer has only emerged in relatively recent times as a key area of research. Nia <jats:italic>et al.</jats:italic> reviewed the physical features that are common to tumors and that limit successful treatment: solid stresses, interstitial fluid pressure, stiffness (rigidity), and architecture and organization of tumor constituents. The authors provide a conceptual framework and discuss the origins of these distinct physical traits of cancer and how they enable and synergize with aberrant cancer biology to fuel cancer initiation, progression, immune evasion, and treatment resistance. </jats:p> <jats:p> <jats:italic>Science</jats:italic> , this issue p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" related-article-type="in-this-issue" xlink:href="10.1126/science.aaz0868">eaaz0868</jats:related-article> </jats:p>

<jats:p>Underrepresented U.S. women of color (UWOC)—Black Americans, Latina Americans, Native Americans, and Indigenous Pacific Islanders—have long been underrepresented among Ph.D. recipients in computer science. The number of computer science Ph.D. degrees annually awarded to UWOC is miniscule. Moreover, even when compared with white women, the discrepancies are overwhelming. The Computer Research Association's Taulbee Survey revealed that in 2019, only seven UWOC (U.S. citizens) received Ph.D. degrees in computer science—a mere 0.43% of all computer science doctorates attained that year and only 2.1% of the doctorates awarded to all women.</jats:p>

<jats:p>As if there were any doubt that U.S. President Donald Trump has no respect for scientists, he now refers to public health scholars as “Fauci and all these idiots.” That's how he's describing experts in virology, immunology, epidemiology, and infectious disease. Never mind that after recovering from coronavirus disease 2019 (COVID-19), Trump suddenly became excited about future vaccines and “Regeneron,” which is what he calls monoclonal antibodies in general. (Regeneron Pharmaceuticals, Inc. is probably thrilled to have achieved the product-brand status of Xerox and Kleenex, but Eli Lilly also has developed promising monoclonals, and more are in clinical trials.) Apparently, no one told the president that scientists from these same fields—many of whom live in “Democrat-run cities” or college towns and are immigrants who wouldn't be here under his policies—created these drugs and carried out the decades of science that made them possible. This paradox of loving the drug but hating the science is nothing new. It's just louder this time.</jats:p>

<jats:p>A roundup of weekly science policy and related news.</jats:p>

<jats:p>Drifting Argo floats will track oxygen loss from global warming and the oceans' ability to soak up carbon.</jats:p>

<jats:p>"Molecular caving" shows archaic humans visited high-altitude cave over long period.</jats:p>

<jats:p>Cases are dropping, but critics question optimistic forecast.</jats:p>

<jats:p>For Akiko Iwasaki, the pandemic has brought new research priorities—and new urgency.</jats:p>

<jats:p>Deleting offensive language is common, but some editors alter reviewers' overall recommendation.</jats:p>